Bhat, Vikas K <br/><br/>
A novel GIP-oxyntomodulin hybrid peptide acting through GIP, glucagon and GLP-1 receptors exhibits weight reducing and anti-diabetic properties.  [electronic resource] 

 -  Biochemical pharmacology  Jun 2013 
 - 1655-62 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1873-2968 
<br/><br/><label>Standard No.: </label>10.1016/j.bcp.2013.03.009  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Amino Acid Sequence<br/>Animals<br/>Blood Glucose--analysis<br/>Cell Line<br/>Cricetinae<br/>Cyclic AMP--biosynthesis<br/>Gastric Inhibitory Polypeptide--chemistry<br/>Glucagon-Like Peptide-1 Receptor<br/>Hypoglycemic Agents--pharmacology<br/>Insulin--blood<br/>Male<br/>Mice<br/>Molecular Sequence Data<br/>Oxyntomodulin--chemistry<br/>Peptides--chemistry<br/>Receptors, Gastrointestinal Hormone--metabolism<br/>Receptors, Glucagon--metabolism<br/>Weight Loss--drug effects